Table 1 Classification of studied groups
Groups | Â |
|---|---|
Group 1(a) | Control: 20 rats. |
Group 1(b) | Pathological control: Twenty streptozotocin-induced diabetic rats |
Group 2(a) | Twenty control rats that received a daily oral dose of the water soluble curcumin derivative (NCD) at a dose of 20 mg/kg body weight for 45 days. |
Group 2(b) | Twenty diabetic rats that received a daily oral dose of the NCD at a dose of 20 mg/kg body weight for 45 days after the induction of DM. |
Group 3(a) | Twenty diabetic rats that received a daily oral dose of the NCD at a dose of 20 mg/kg body weight for 45 days after induction of DM and a weekly intraperitoneal (i.p.) dose of HO-1 inhibitor, ZnPP IX (10 μmol/Kg dissolved in sodium hydroxide 0.1 N and sodium chloride 0.9% and pH adjusted to pH 7.4) for 6 weeks. |
Group 3(b) | Twenty diabetic rats that received a weekly i.p. dose of HO-1 inhibitor, ZnPP IX (10 μmol/Kg dissolved in sodium hydroxide 0.1 N and sodium chloride 0.9% and pH adjusted to pH 7.4) for 6 weeks. |
Group 4 | Twenty diabetic rats that received a daily oral dose of pure curcumin at a dose of 20 mg/kg body weight for 45 days after induction of DM. |